Mycenax Biotech Finishes Phase II Trial of Biosimilar Drug

October 28, 2009 -- Mycenax Biotech of Taiwan, a protein drug development company, reported TuNEX its biosimilar version of etanercept, a rheumatoid arthritis and psoriasis treatment, successfully completed a Phase I trial in South Korea and a Phase I/II trial in Taiwan. Etanercept is a TNF inhibitor marketed as Enbrel by Amgen (NSDQ: AMGN) and Wyeth (NYSE: WYE) and in Japan by Takeda Pharma. More details... Stock Symbol: (GreTai: 4726)